Gold sponsor:

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions" on a daily basis.

Silver sponsor:

Crucell N.V. is a global biopharmaceutical company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people.

Silver sponsor:

MediVas uses its novel polymer technology to manipulate and enhance the properties of therapeutic drugs and biologics to improve safety, efficacy and ease of use.  This technology can be employed with new chemical entities or with generic drugs, from small synthetic compounds to large recombinant proteins.  Initiated by an exclusive license from Cornell University, MediVas has developed a unique platform of biocompatible, biodegradable synthetic polymers for medicinal injection or implantation as drug delivery or tissue regeneration materials. These polymers are composed of simple, natural ingredients and can be manufactured efficiently to scale.  Development of this family of polymers has been a joint effort between Cornell and MediVas.  The Company’s patent estate currently exceeds 60 issued or pending US patents.
We utilize our unique biomaterials and formulation expertise to develop, both with partners and on our own, innovative drug products in major therapeutic areas.  We enter select collaborations to develop novel product candidates, based on new or existing drugs, incorporating our patented technology.  We also develop our own proprietary products applying our biomaterial technology and formulation expertise to create pharmaceutical products.  For more information visit our website at www.MediVas.com.

Silver sponsor:

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6,100 employees in 47 countries worldwide.

Session sponsor:

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The company is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Innovative showcase sponsor:

Immune Targeting Systems is a London based biotech company developing synthetic vaccines for mutating viruses. ITS’ lead program (FP-01) is a synthetic universal influenza vaccine targeting all potential seasonal and pandemic flu strains. FP-01’s pandemic claim remains unaffected by the emergence of swine H1N1 and avian H5N1 influenza and was specifically designed to counter new drifted and shifted strains. FP-01 will enter the clinic in early 2010. ITS’ broadly applicable and proprietary T-cell vaccine platform delivers rationally selected antigens to the immune system and achieves potent immune responses without requiring adjuvants. Antigens are highly conserved across all viral strains and relevant for a global human population. Vaccine manufacturing scalability and stability are also key vaccine design features. Candidates for Hepatitis-B & C, HIV & FIV are in the lead-optimisation phase and fluoropeptides are also applicable to RSV, Herpes, Dengue, HPV, TB, Malaria and cancers. The Company welcomes potential investor and partnering discussions. 

Exhibitor:

GE Healthcare provides life science research products and biopharmaceutical manufacturing technologies. Over 90% of the current biopharmaceuticals therapies on the market are manufactured utilizing chromatography media from GE Healthcare. In addition, our service organization helps you improve productivity and reduce costs associated with the upkeep of laboratory and manufacturing equipment. 

Exhibitor:

i3 is an international CRO, providing customised outsourcing solutions to its clients.  Our therapeutic expertise includes Oncology, CNS, Respiratory, Infectious, Cardiovascular, Endocrinology & Metabolic Diseases.  With a global footprint across the Americas, Europe, Asia-Pac & India, i3 offers a tailored solution to individual clients, from outsourcing entire clinical trials to in-sourcing high quality staff in all areas of clinical research.

Exhibitor:

Mycosafe is recognised as a leading GMP certified company specialised in contract mycoplasma biosafety testing and related consultancy and R&D services for the mycoplasma biosafety and prevention control of cell lines, biological and biopharmaceutical products, and vaccines.

ViruSure is a GLP certified company specialising in the virus and prion biosafety testing of biopharmaceutical products and vaccines. It has established itself as a leader in contract safety testing with a solid basis in quality, risk based approaches to virus safety.

Exhibitor:

Pall is the global leader in the rapidly growing field of filtration, separations and purification.  Pall's business is organized around two broad markets: Life Sciences and Industrial.  The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicines, semiconductors, water purification, aerospace and broad industrial markets.  The total revenue for fiscal year 2007 amounts to US$2.2 Billion.  The Company is headquartered in East Hills, New York, with extensive operations throughout the world.